Australia markets open in 6 hours 34 minutes
  • ALL ORDS

    7,238.70
    -39.90 (-0.55%)
     
  • AUD/USD

    0.7105
    +0.0138 (+1.98%)
     
  • ASX 200

    6,992.70
    -37.10 (-0.53%)
     
  • OIL

    91.76
    +1.26 (+1.39%)
     
  • GOLD

    1,813.20
    +0.90 (+0.05%)
     
  • BTC-AUD

    33,659.54
    +922.98 (+2.82%)
     
  • CMC Crypto 200

    562.71
    +31.49 (+5.93%)
     

Immunovant to Present at the Stifel 2021 Virtual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will provide a corporate overview at the Stifel 2021 Virtual Healthcare Conference, taking place November 15-17, 2021.

Stifel 2021 Virtual Healthcare Conference Presentation

Date:

Wednesday, November 17th, 2021

Time:

2:00pm Eastern Time

Webcast:

The presentation will be available via webcast and can be accessed at the Investor Relations section of the Company’s website, located at www.immunovant.com

About Immunovant, Inc.

Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases. Immunovant is developing IMVT-1401 (batoclimab), a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.

Contact:

Tom Dorney, MS, MBA
Director, Investor Relations & Strategy
Immunovant, Inc.
info@immunovant.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting